Brainstorm Cell Therapeutics (BCLI) Tops Q1 EPS by 15c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
• Benchmark Reiterates Buy Rating on IMAX Corporation (IMAX), Highlights 'The Odyssey' Potential